George M. Gould

Protein Design Labs, Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a company of development of humanized antibodies, It has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products.

Tapestry Pharmaceuticals, Inc. develops, manufactures, and markets an anti-cancer pharmaceutical called Paclitaxel. It focuses on the development of proprietary therapies for the treatment of cancer, new products and technologies may involve the examination of individual molecules and classes of compounds. The company was founded in 1991 and is headquartered in Ankeny, IA.

Gibbons Del Deo Dolan Griffinger & Vecchione provides legal services. The company is headquartered in Newark, NJ.

PharmaGenics, Inc. develops therapeutic products for cancer. The American company was founded by Mike I. Sherman. PharmaGenics was acquired by Genzyme Corp., part of Sanofi from April 08, 2011 on June 18, 1997 for $112 million.

Gibbons P.C. provides legal services. It offers business and commercial litigation, corporate, government affairs, criminal defense and employment law. The company was founded in 1926 and is headquartered in Newark, NJ.

Supratek Pharma, Inc. develops drugs and related oncology therapeutic products. It offers injectable chemotherapeutic that enhances or enables an approved anticancer drug. The firm’s products include SP1014C - a novel cabazitaxel against drug resistant prostate cancer, SP1030C - novel bendamustine against chronic lymphocytic leukemia and non-Hodgkin’s lymphoma and SP1049C - a novel injectable anthracycline platform drug against chemoresistant cancers. The company was founded by Valery Alakhov in 1994 and is headquartered in Pointe-Claire, Canada.

BioSpecifics Technologies Corp. engages in the development of an injectable collagenase clostridium histolyticum for multiple indications. It sells its products under the brand XIAFLEX. The company was founded in 1990 and is headquartered in Lynbrook, NY.